GARIN3
gene geneOn this page
Also known as MGC26988GARI-L3
Summary
GARIN3 (golgi associated RAB2 interactor family member 3, HGNC:28397) is a protein-coding gene on chromosome 5q33.3, encoding Golgi-associated RAB2 interactor protein 3 (Q8TC56). May be involved in RNA biogenesis.
Predicted to be involved in gene expression and vacuole organization. Predicted to act upstream of or within several processes, including acrosome assembly; binding activity of sperm to zona pellucida; and penetration of zona pellucida. Located in nucleus.
Source: NCBI Gene 153745 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 125 total
- MANE Select transcript:
NM_130899
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28397 |
| Approved symbol | GARIN3 |
| Name | golgi associated RAB2 interactor family member 3 |
| Location | 5q33.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MGC26988, GARI-L3 |
| Ensembl gene | ENSG00000170613 |
| Ensembl biotype | protein_coding |
| OMIM | 619883 |
| Entrez | 153745 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000302938
RefSeq mRNA: 1 — MANE Select: NM_130899
NM_130899
CCDS: CCDS4335
Canonical transcript exons
ENST00000302938 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001164915 | 157161846 | 157163658 |
| ENSE00001164921 | 157165563 | 157166264 |
Expression profiles
Bgee: expression breadth broad, 16 present calls, max score 90.95.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0501 / max 41.4998, expressed in 3 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 64513 | 0.0501 | 3 |
Top tissues by expression
243 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 90.95 | gold quality |
| sperm | CL:0000019 | 89.35 | silver quality |
| left testis | UBERON:0004533 | 86.16 | gold quality |
| right testis | UBERON:0004534 | 85.83 | gold quality |
| testis | UBERON:0000473 | 83.26 | gold quality |
| parotid gland | UBERON:0001831 | 62.60 | gold quality |
| myocardium | UBERON:0002349 | 58.98 | gold quality |
| vena cava | UBERON:0004087 | 57.64 | gold quality |
| adult organism | UBERON:0007023 | 55.55 | gold quality |
| cardia of stomach | UBERON:0001162 | 54.44 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 53.53 | gold quality |
| lateral globus pallidus | UBERON:0002476 | 52.93 | gold quality |
| oocyte | CL:0000023 | 49.29 | gold quality |
| buccal mucosa cell | CL:0002336 | 47.80 | gold quality |
| lower lobe of lung | UBERON:0008949 | 47.18 | silver quality |
| trachea | UBERON:0003126 | 46.90 | gold quality |
| vastus lateralis | UBERON:0001379 | 46.80 | gold quality |
| quadriceps femoris | UBERON:0001377 | 46.65 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 46.05 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 44.94 | gold quality |
| body of tongue | UBERON:0011876 | 44.59 | gold quality |
| layer of synovial tissue | UBERON:0007616 | 44.58 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 43.83 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 43.37 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 43.27 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 43.12 | gold quality |
| tongue | UBERON:0001723 | 42.99 | gold quality |
| nipple | UBERON:0002030 | 42.94 | gold quality |
| globus pallidus | UBERON:0001875 | 42.81 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 42.65 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-134144 | yes | 784.98 |
| E-ANND-3 | no | 2.30 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
9 targeting GARIN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-17-3P | 99.55 | 66.77 | 1311 |
| HSA-MIR-4292 | 99.16 | 65.57 | 1767 |
| HSA-MIR-6791-5P | 99.16 | 65.92 | 1844 |
| HSA-MIR-203B-3P | 97.82 | 66.27 | 979 |
| HSA-MIR-509-3-5P | 97.21 | 67.74 | 1517 |
| HSA-MIR-509-5P | 97.21 | 67.90 | 1512 |
| HSA-MIR-4418 | 97.04 | 67.16 | 1372 |
| HSA-MIR-4653-3P | 96.26 | 67.03 | 725 |
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Garin3 | ENSMUSG00000020401 |
| rattus_norvegicus | Garin3 | ENSRNOG00000021425 |
Paralogs (7): GARIN1B (ENSG00000135248), GARIN5A (ENSG00000142530), GARIN4 (ENSG00000162771), GARIN2 (ENSG00000172717), GARIN5B (ENSG00000180043), GARIN6 (ENSG00000180219), GARIN1A (ENSG00000205085)
Protein
Protein identifiers
Golgi-associated RAB2 interactor protein 3 — Q8TC56 (reviewed: Q8TC56)
All UniProt accessions (2): Q8TC56, A0A140VJJ4
UniProt curated annotations — full annotation on UniProt →
Function. May be involved in RNA biogenesis.
Subunit / interactions. Interacts (via N-terminus) with RAB2B (in GTP-bound form). Interacts with FRG1.
Subcellular location. Golgi apparatus. Nucleus. Cajal body.
Tissue specificity. Expressed in adult spermatocytes and spermatids (at protein level).
Similarity. Belongs to the GARIN family.
RefSeq proteins (1): NP_570969* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR022168 | GARIL-like_Rab2B-bd | Domain |
Pfam: PF12480
UniProt features (15 total): compositionally biased region 6, sequence variant 3, region of interest 2, chain 1, modified residue 1, sequence conflict 1, short sequence motif 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8TC56-F1 | 51.61 | 0.12 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 592
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 89 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GOBP_SINGLE_FERTILIZATION, GOBP_VESICLE_ORGANIZATION, GOBP_MALE_GAMETE_GENERATION, GOBP_SECRETORY_GRANULE_ORGANIZATION, GOBP_CELLULAR_COMPONENT_ASSEMBLY_INVOLVED_IN_MORPHOGENESIS, GOBP_CILIUM_MOVEMENT, GOBP_SPERM_EGG_RECOGNITION, GOBP_CILIUM_OR_FLAGELLUM_DEPENDENT_CELL_MOTILITY, GOBP_ACROSOME_ASSEMBLY, GOBP_ORGANELLE_ASSEMBLY, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_MULTI_MULTICELLULAR_ORGANISM_PROCESS, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION
GO Biological Process (7): cell morphogenesis (GO:0000902), acrosome assembly (GO:0001675), binding of sperm to zona pellucida (GO:0007339), penetration of zona pellucida (GO:0007341), flagellated sperm motility (GO:0030317), spermatid development (GO:0007286), single fertilization (GO:0007338)
GO Molecular Function (0):
GO Cellular Component (4): nucleus (GO:0005634), Golgi apparatus (GO:0005794), Cajal body (GO:0015030), sperm head (GO:0061827)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| intracellular membrane-bounded organelle | 2 |
| anatomical structure morphogenesis | 1 |
| developmental process involved in reproduction | 1 |
| spermatid development | 1 |
| cellular component assembly involved in morphogenesis | 1 |
| cellular process involved in reproduction in multicellular organism | 1 |
| secretory granule organization | 1 |
| organelle assembly | 1 |
| sperm-egg recognition | 1 |
| single fertilization | 1 |
| multi-multicellular organism process | 1 |
| multicellular organismal reproductive process | 1 |
| cilium-dependent cell motility | 1 |
| cilium movement involved in cell motility | 1 |
| sperm motility | 1 |
| germ cell development | 1 |
| spermatid differentiation | 1 |
| fertilization | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| nuclear ribonucleoprotein granule | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
374 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| GARIN3 | SPEM3 | A0A1B0GUW6 | 576 |
| GARIN3 | SPATA31F1 | Q6ZU69 | 539 |
| GARIN3 | MORN5 | Q5VZ52 | 519 |
| GARIN3 | C6orf118 | Q5T5N4 | 507 |
| GARIN3 | PPP1R2B | Q6NXS1 | 507 |
| GARIN3 | PROCA1 | Q8NCQ7 | 463 |
| GARIN3 | SPATA3 | Q8NHX4 | 447 |
| GARIN3 | OR10A4 | Q9H209 | 431 |
| GARIN3 | NT5C1B | Q96P26 | 419 |
| GARIN3 | FRG1 | Q14331 | 418 |
| GARIN3 | CCDC136 | Q96JN2 | 414 |
| GARIN3 | ZNF75A | Q96N20 | 400 |
| GARIN3 | LELP1 | Q5T871 | 392 |
| GARIN3 | ROPN1 | Q9HAT0 | 389 |
| GARIN3 | TMEM202 | A6NGA9 | 386 |
IntAct
2 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| Prdm16 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (3): FAM71B (Affinity Capture-MS), FAM71B (Affinity Capture-MS), FAM71B (Affinity Capture-MS)
ESM2 similar proteins: A2ASS6, A8DYP0, E9QMW4, G4SLH0, J7M799, M9MRD1, O15061, O43491, O55103, O70318, O75952, O77788, P07197, P08553, P08855, P11799, P12839, P16053, P27321, P51125, P54938, P57786, P82179, P83741, Q06637, Q13061, Q23551, Q28820, Q4R3X7, Q63425, Q66H38, Q696W0, Q6TS35, Q70IV5, Q7Z589, Q7ZUV7, Q86TC9, Q8BMB0, Q8TC56, Q8WZ42
Diamond homologs: A1L3C1, B2RXB0, D3YV92, Q2KIP3, Q2YDE8, Q32L49, Q3UZD7, Q4R323, Q5STT6, Q66H38, Q68FV5, Q6IPT2, Q6NXP2, Q8IYT1, Q8N5Q1, Q8N9W8, Q8NEG0, Q8TC56, Q95K21, Q95K27, Q96KD3, Q5RJN7
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
125 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 110 |
| Likely benign | 14 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
165 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 5:157163666:A:T | acceptor_gain | 1.0000 |
| 5:157165562:CCA:C | donor_gain | 1.0000 |
| 5:157163656:AGCCT:A | acceptor_gain | 0.9900 |
| 5:157163658:CCTA:C | acceptor_gain | 0.9900 |
| 5:157163665:C:CT | acceptor_gain | 0.9900 |
| 5:157165556:GGCTT:G | donor_loss | 0.9900 |
| 5:157165557:GCTT:G | donor_loss | 0.9900 |
| 5:157165558:CTTAC:C | donor_loss | 0.9900 |
| 5:157165559:TTA:T | donor_loss | 0.9900 |
| 5:157165560:TA:T | donor_loss | 0.9900 |
| 5:157165561:A:AC | donor_gain | 0.9900 |
| 5:157165562:C:CA | donor_loss | 0.9900 |
| 5:157165562:C:CC | donor_gain | 0.9900 |
| 5:157163657:GC:G | acceptor_gain | 0.9800 |
| 5:157163657:GCCT:G | acceptor_gain | 0.9800 |
| 5:157163658:CC:C | acceptor_loss | 0.9800 |
| 5:157163659:C:CC | acceptor_gain | 0.9800 |
| 5:157163661:A:C | acceptor_gain | 0.9800 |
| 5:157165684:T:TA | donor_gain | 0.9800 |
| 5:157165685:C:A | donor_gain | 0.9800 |
| 5:157163655:CAGC:C | acceptor_gain | 0.9700 |
| 5:157163658:CCTAT:C | acceptor_gain | 0.9700 |
| 5:157163665:C:T | acceptor_gain | 0.9700 |
| 5:157164738:G:A | donor_gain | 0.9700 |
| 5:157165562:CCACT:C | donor_gain | 0.9700 |
| 5:157163654:GCAGC:G | acceptor_gain | 0.9600 |
| 5:157163655:CAGCC:C | acceptor_gain | 0.9600 |
| 5:157165562:C:CT | donor_gain | 0.9600 |
| 5:157164746:G:C | donor_gain | 0.9500 |
| 5:157163656:AGC:A | acceptor_gain | 0.9400 |
AlphaMissense
3969 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 5:157165667:A:G | W168R | 0.986 |
| 5:157165667:A:T | W168R | 0.986 |
| 5:157165665:C:A | W168C | 0.985 |
| 5:157165665:C:G | W168C | 0.985 |
| 5:157166016:A:C | F51L | 0.985 |
| 5:157166016:A:T | F51L | 0.985 |
| 5:157166018:A:G | F51L | 0.985 |
| 5:157165674:A:C | F165L | 0.982 |
| 5:157165674:A:T | F165L | 0.982 |
| 5:157165676:A:G | F165L | 0.982 |
| 5:157165778:A:G | S131P | 0.981 |
| 5:157165714:A:G | L152P | 0.979 |
| 5:157165750:A:G | L140P | 0.979 |
| 5:157165719:A:C | F150L | 0.975 |
| 5:157165719:A:T | F150L | 0.975 |
| 5:157165721:A:G | F150L | 0.975 |
| 5:157166022:A:C | S49R | 0.975 |
| 5:157166022:A:T | S49R | 0.975 |
| 5:157166024:T:G | S49R | 0.975 |
| 5:157165744:A:G | L142P | 0.974 |
| 5:157165747:C:G | R141P | 0.972 |
| 5:157165906:A:T | V88D | 0.970 |
| 5:157166017:A:G | F51S | 0.970 |
| 5:157165708:A:G | L154S | 0.969 |
| 5:157165753:T:G | Q139P | 0.969 |
| 5:157165726:C:G | R148P | 0.965 |
| 5:157165675:A:C | F165C | 0.959 |
| 5:157165780:A:G | I130T | 0.958 |
| 5:157165780:A:C | I130S | 0.957 |
| 5:157165666:C:G | W168S | 0.955 |
dbSNP variants (sampled 300 via entrez): RS1000851871 (5:157167324 G>T), RS1000895882 (5:157167082 C>T), RS1001806042 (5:157162515 C>T), RS1002550966 (5:157166434 T>G), RS1002755969 (5:157163980 T>G), RS1003472073 (5:157163848 G>T), RS1004524530 (5:157161916 C>T), RS1004747499 (5:157163773 G>A), RS1004968515 (5:157167677 C>A,G), RS1005881468 (5:157164607 C>T), RS1006208712 (5:157164708 C>G), RS1006807968 (5:157166046 G>A,C,T), RS1007166525 (5:157166346 C>T), RS1007560461 (5:157161855 A>C), RS1007754139 (5:157167920 A>G)
Disease associations
OMIM: gene MIM:619883 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST003518_6 | Daytime sleep phenotypes | 7.000000e-06 |
| GCST009597_71 | Multiple sclerosis | 3.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007828 | daytime rest measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
5 total (human), top 5 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | increases expression, decreases methylation | 2 |
| CGP 52608 | affects binding, increases reaction | 1 |
| Resveratrol | decreases expression, affects cotreatment | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
| Silicon Dioxide | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.